It is very uncertain whether infliximab changes serious adverse events (at 54 weeks) compared with placebo (very low certainty).
It is very uncertain whether infliximab combined with purine analogues changes serious adverse events (at 48 weeks to 2 years) compared with purine analogues (very low certainty).
It is very uncertain whether shock wave lithotripsy changes serious adverse events or complications of treatment compared with ureteroscopy with holmium laser or pneumatic lithotripsy (very low certainty).
Shock wave lithotripsy may leads to lower serious adverse events or complications of treatment compared with mini‐percutaneous nephrolithotripsy (low certainty).
It is very uncertain whether shock wave lithotripsy changes serious adverse events or complications of treatment compared with dissolution therapy (very low certainty).
It is very uncertain whether percutaneous nephrolithotripsy changes serious adverse events or complications of treatments compared with tubeless percutaneous nephrolithotripsy (very low certainty).
The review found no eligible studies for this question.
Certolizumab pegol showed no clear difference in serious adverse events during remission maintenance treatment(1 RCT,… compared with placebo (low certainty).